Phase III randomized comparative study of combination therapy with CDDP and TS-1 vs. combination therapy with CDDP and Docetaxel in stage IIIB/IV non-small cell lung cancer
Not Applicable
- Conditions
- Stage IIIB/IV or ppstoperative recurrent non-small sell lung cancer
- Registration Number
- JPRN-UMIN000000608
- Lead Sponsor
- The Tokyo cooperative oncology group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 600
Inclusion Criteria
Not provided
Exclusion Criteria
1.With adjuvant chemotherapy 2.History of serious drug allergy 3.Active concomitant malignancy 4.Serious complications 5.Proven or suspected infections diseases 6.Symptomatic brain metastasis 7.Watery diarrhea or Chronic constipation 8.Pleural effusion,peritoneal fluid,and pericardial fluid 9.Concomitant therapy with another anticancer drug or flucytocine 10.Pregnancy,breast feeding or wish of future bearing 11.Mental disease or psychotic manifestation 12.It participated in the development clinical trial of and others within 1 month 13.Other conditions not suitable for this study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method overall survival
- Secondary Outcome Measures
Name Time Method PFS TTF Response rate Adverse event QO